Paper Details

  1. Home
  2. Paper Details

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.

Author: Almeciga-PintoIngrid, JonesSimon S, NorthBrian J, QuayleSteven N, TamangDavid, YangMin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Thalidomide-based immunomodulatory drugs (IMiDs) are effective treatments for multiple myeloma. This study investigated the potential benefits of combining pomalidomide, an IMiD, with citarinostat, a selective HDAC6 inhibitor. The study found that the combination treatment showed synergistic effects in both in vitro and in vivo models. The combination led to greater apoptosis and cell cycle arrest, resulting in increased tumor growth inhibition.
Paper Details　
Original Abstract of the Article :
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal antibo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338861/

データ提供：米国国立医学図書館（NLM）

Pomalidomide and ACY-241: A Synergistic Oasis in the Desert of Multiple Myeloma

Multiple myeloma, a type of blood cancer, presents a challenging landscape, leaving patients facing a battle against a relentless disease. This study explores the potential of a combination therapy, involving pomalidomide, a medication already used to treat multiple myeloma, and ACY-241, a selective inhibitor of histone deacetylase 6 (HDAC6). The study, akin to a careful exploration of the desert for hidden resources, seeks to determine if this synergistic duo can enhance the effectiveness of treatment.

A Synergistic Oasis: Combating Cancer with Combined Forces

The study reveals that the combination of pomalidomide and ACY-241 exhibits a synergistic effect in combating multiple myeloma, a discovery like finding a hidden oasis that provides a potent and effective weapon against the disease. This synergistic approach, akin to combining the strengths of different desert tribes, leads to greater tumor growth inhibition and improved survival outcomes.

A Promising Future: Navigating the Desert of Cancer Treatment

This study offers a glimmer of hope for individuals battling multiple myeloma, highlighting the potential of combining existing medications to create a more potent and effective treatment strategy. This approach, akin to combining resources and strategies in a desert expedition, opens up new avenues for navigating the challenging landscape of cancer treatment, bringing us closer to a more peaceful and resilient future for those living with this disease.

Dr.Camel's Conclusion

The desert of cancer treatment is a demanding and often unforgiving landscape, leaving patients feeling lost and vulnerable. This study reveals the potential of combining therapies to create a more powerful and effective approach, offering a refreshing oasis of hope in this challenging journey. The findings underscore the importance of continuing research and innovation, seeking new and synergistic combinations that can help us conquer the deserts of disease and provide a brighter future for those in need.

Date :
  1. Date Completed 2017-08-25
  2. Date Revised 2019-02-08
Further Info :

Pubmed ID

28264055

DOI: Digital Object Identifier

PMC5338861

Related Literature

Article Analysis
・Side Effects of pomalidomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.